Clinical trial
A Study of 141W94 in Combination With Other Anti-HIV Drugs
NCT00002372 · Glaxo Wellcome, Industry · Completed
Key facts
| NCT number | NCT00002372 |
|---|---|
| Title | A Study of 141W94 in Combination With Other Anti-HIV Drugs |
| Official title | A Phase I/II Screening Trial to Identify Potential Partner Compounds to Use in Combination With 141W94 |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Indinavir sulfate, Amprenavir, Nelfinavir mesylate, Saquinavir |
| Enrollment | 48 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: